BeiGene
BGNE
#881
Rank
โ‚ฌ20.01 B
Marketcap
182,28ย โ‚ฌ
Share price
1.71%
Change (1 day)
0.79%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of June 2024 : โ‚ฌ0.98 B

According to BeiGene 's latest financial reports the company's total debt is โ‚ฌ0.98 B. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚ฌ0.84 B51.27%
2022-12-31โ‚ฌ0.55 B-8.9%
2021-12-31โ‚ฌ0.61 B32.81%
2020-12-31โ‚ฌ0.45 B86.12%
2019-12-31โ‚ฌ0.24 B42.62%
2018-12-31โ‚ฌ0.17 B26.16%
2017-12-31โ‚ฌ0.13 B735.44%
2016-12-31โ‚ฌ16.43 M-13.7%
2015-12-31โ‚ฌ19.04 M67.49%
2014-12-31โ‚ฌ11.36 M-42.61%
2013-12-31โ‚ฌ19.8 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.24 B-75.28%๐Ÿ‡บ๐Ÿ‡ธ USA